ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Pfizer pulls sickle cell treatment Oxbryta off global markets

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks

September 25, 2024

Exclusive: Noetik raises $40M Series A to advance AI ambitions in cancer — with an unlikely lead investor

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 29, 2024

Memora Health, Intermountain Partner on Personalized, AI-Powered Care

What You Should Know: – Memora Health, a provider of intelligent care enablement platforms, and Intermountain Health, an integrated healthcare delivery system, today announced a

March 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.